Navigation Links
Lumension Provides Leading e-Commerce Company Proactive Endpoint Security at a High Return
Date:12/16/2008

The New Ogren Group study quantifies ROI of Lumension's integrated application whitelisting and vulnerability management solutions inside a real-world enterprise environment

Scottsdale, Ariz. (PRWEB) December 16, 2008 -- Demonstrating the value automated tools that align security and IT functions have on the enterprise, Lumension Security™, Inc., a leading global security management company, today made available a ROI customer case study with analysis conducted by the Ogren Group. The key findings of the report found that EC Suite, a major processor of credit card transactions for e-commerce organizations, saved considerable time and effort in their IT and security operations because of the preventive security measures and procedures available in Lumension's security solutions.

Lumension's advanced application whitelisting protects against malware and viral programs, while improving total data security and overall system performance to meet the needs of both IT security and IT operations. Additionally, Lumension's Data Protection Solution provides the control and detailed forensics required to analyze and update security polices. As a result, organizations, such as EC Suite, can more efficiently detect risks, deploy patches and defend business information across a distributed environment to positively impact a company's bottom line.

"IT security is difficult to justify from a financial return basis as security products seldom tie directly to revenue," said Eric Ogren, principal analyst Ogren Group. "Adopting preventive, proactive security solutions to manage endpoint risk will improve security coverage of all devices in the network and multiple applications, and it will save operational expenses associated with attacks or inferior products. That's a good combination that works for EC Suite."

The Ogren Group's analysis found EC Suite achieved an impressive 258 percent rate of return in the first year of operating Lumension security products, with a 964 percent average rate of return over the first three years. This calculation is based on the year-over-year cost savings of over $226,700 that EC Suite derives from integrating Lumension's vulnerability patch process with its application control whitelisting technology.

"Leveraging Lumension's security solutions has allowed us to take a proactive, integrated approach to operational security," said William Bell, director of security, ECSuite.com. "As a result, we feel better-prepared to address the security challenges, such as increased spyware, Trojan attacks and intentional or unintentional information leakages that confront our organization, to preserve the integrity of our business."

Lumension's Endpoint Protection Suite protects against targeted threats and enables only authorized applications and devices to execute or connect to a network server, terminal services server, thin client, laptop or desktop. Lumension's suite simplifies the discovery phase so that administrators can uncover all of the applications that are executing on the endpoints. Once known what applications are on the network, a policy can be established and enforced.

In addition, Lumension delivers the only vulnerability management solution that fully integrates network scanning, agent-based assessment and remediation in a single management console. For more information and to access the new case study: "Lumension Security: a Case Study in Proactively Managing Endpoint Risk."

For a free 30-day trial of Lumension's award-winning solutions, please visit lumension.com.

About Lumension Security™, Inc.

Lumension Security™, formed by the combination of PatchLink® Corporation and SecureWave® S.A., is a recognized, global security management company, providing unified protection and control of enterprise endpoints for more than 5,100 customers and 14 million nodes worldwide. Leveraging its proven Positive Security Model, Lumension Security enables organizations to effectively manage risk at the endpoint by delivering best-of-breed, policy-based solutions that simplify the entire security management lifecycle. This includes automated asset discovery, vulnerability assessment, remediation and validation; security configuration management; application control and device control; extensive policy compliance reporting; and integration with leading network access control solutions. Founded in 1991, Lumension is headquartered in Scottsdale, Arizona, with offices worldwide, including Virginia, Florida, Luxembourg, the United Kingdom, Spain, Australia, Hong Kong and Singapore. More information can be found at lumension.com.

Lumension Security, the Lumension logo, PatchLink® and Sanctuary® are trademarks or registered trademarks of Lumension Security. All other trademarks are the property of their respective owners.

###

Read the full story at http://www.prweb.com/releases/endpoint/security/prweb1755974.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Lumension Security Announces General Availability of Sanctuary Endpoint Protection and Data Protection Suite to Safeguard Data and Privacy
2. Lumension Security To Showcase Vulnerability Management Expertise With Whitehatworld.com Webcast
3. Lumension Security Launches Interactive Office Game To Educate IT Professionals On 10 Most Common Security Risks Within The Workplace
4. Lumension Security Debuts New Customer Testimonial Video
5. Lumension Security Launches Podcast On Application Whitelisting: Keep The Bad Guys Out - Let The Good Guys In
6. Lumension Security Receives Frost & Sullivan 2008 Global Market Penetration Leadership Award
7. Lumension Security To Host Industry Webinar On Staying Ahead Of Threats
8. Lumension Security to Host Industry Webinar on Protecting Vital Business Data
9. Lumension Uncovers Results of Security Data Protection Survey
10. Study provides hope that some transplant patients could live free of antirejection drugs
11. Study provides hope that some transplant patients could live free of anti-rejection drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lumension Provides Leading e-Commerce Company Proactive Endpoint Security at a High Return
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: